

Lauren K Truby

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3292852/publications.pdf>

Version: 2024-02-01

41
papers

1,603
citations

331670

21
h-index

315739

38
g-index

41
all docs

41
docs citations

41
times ranked

1913
citing authors

#	ARTICLE	IF	CITATIONS
1	Donation After Circulatory Death in Heart Transplantation: History, Outcomes, Clinical Challenges, and Opportunities to Expand the Donor Pool. <i>Journal of Cardiac Failure</i> , 2022, 28, 1456-1463.	1.7	18
2	Increased Opportunities for Transplantation for Women in the New Heart Allocation System. <i>Journal of Cardiac Failure</i> , 2022, 28, 1149-1157.	1.7	12
3	C-Reactive Protein Levels Predict Outcomes in Continuous-Flow Left Ventricular Assist Device Patients. <i>ASAIO Journal</i> , 2021, Publish Ahead of Print, 884-890.	1.6	4
4	ECMO as a Bridge to Left Ventricular Assist Device or Heart Transplantation. <i>JACC: Heart Failure</i> , 2021, 9, 281-289.	4.1	32
5	Impact of heart failure drug therapy on rates of gastrointestinal bleeding in LVAD recipients: An INTERMACS analysis. <i>International Journal of Artificial Organs</i> , 2021, 44, 965-971.	1.4	8
6	Advanced heart failure patients supported with ambulatory inotropic therapy: What defines success of therapy?. <i>American Heart Journal</i> , 2021, 239, 11-18.	2.7	2
7	Incidence and impact of primary graft dysfunction in adult heart transplant recipients: A systematic review and meta-analysis. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 642-651.	0.6	25
8	Proteomic profiling identifies CLEC4C expression as a novel biomarker of primary graft dysfunction after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1589-1598.	0.6	12
9	Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy. <i>Cardiovascular Diabetology</i> , 2021, 20, 161.	6.8	8
10	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2021, 154, 123-126.	1.6	1
11	Critically appraising the 2018 United Network for Organ Sharing donor allocation policy. <i>Current Opinion in Anaesthesiology</i> , 2021, Publish Ahead of Print, .	2.0	5
12	Impact of Obesity on Ventricular Assist Device Outcomes. <i>Journal of Cardiac Failure</i> , 2020, 26, 287-297.	1.7	23
13	Potential for donation after circulatory death heart transplantation in the United States: Retrospective analysis of a limited UNOS dataset. <i>American Journal of Transplantation</i> , 2020, 20, 525-529.	4.7	23
14	Psychosocial Risk and Its Association With Outcomes in Continuous-Flow Left Ventricular Assist Device Patients. <i>Circulation: Heart Failure</i> , 2020, 13, e006910.	3.9	33
15	Identification of Undetected Monogenic Cardiovascular Disorders. <i>Journal of the American College of Cardiology</i> , 2020, 76, 797-808.	2.8	17
16	Advanced Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 523-536.	4.1	154
17	Impact of Induction Immunosuppression on Post-Transplant Outcomes of Patients Bridged with Contemporary Left Ventricular Assist Devices. <i>ASAIO Journal</i> , 2020, 66, 261-267.	1.6	6
18	Sex Differences in Quality of Life and Clinical Outcomes in Patients With Advanced Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006134.	3.9	29

#	ARTICLE	IF	CITATIONS
19	EC-VAD: Combined Use of Extracorporeal Membrane Oxygenation and Percutaneous Microaxial Pump Left Ventricular Assist Device. <i>ASAIO Journal</i> , 2019, 65, 219-226.	1.6	50
20	Red Cell Distribution Width Predicts 90 Day Mortality in Continuous-Flow Left Ventricular Assist Device Patients. <i>ASAIO Journal</i> , 2019, 65, 233-240.	1.6	4
21	Impact of Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices on Posttransplantation Mortality. <i>Circulation</i> , 2019, 140, 459-469.	1.6	49
22	Management of primary graft failure after heart transplantation: Preoperative risks, perioperative events, and postoperative decisions. <i>Clinical Transplantation</i> , 2019, 33, e13557.	1.6	13
23	Sex-Related Differences in Use and Outcomes of Left Ventricular Assist Devices as Bridge to Transplantation. <i>JACC: Heart Failure</i> , 2019, 7, 250-257.	4.1	66
24	Response by Truby and Topkara to Letter Regarding Article, "Impact of Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices on Posttransplantation Mortality: A Propensity-Matched Analysis of the United Network of Organ Sharing Database". <i>Circulation</i> , 2019, 140, e942-e943.	1.6	0
25	Ventricular Assist Device Utilization in Heart Transplant Candidates. <i>Circulation: Heart Failure</i> , 2018, 11, e004586.	3.9	44
26	Prognostic Impact of Pulmonary Artery Pulsatility Index (PAPi) in Patients With Advanced Heart Failure: Insights From the ESCAPE Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 453-459.	1.7	82
27	Mechanical Circulatory Support Device Utilization and Heart Transplant Waitlist Outcomes in Patients With Restrictive and Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2018, 11, e004665.	3.9	22
28	Incidence and Impact of On-Cardiopulmonary Bypass Vasoplegia During Heart Transplantation. <i>ASAIO Journal</i> , 2018, 64, 43-51.	1.6	32
29	Aortic Insufficiency During Contemporary Left Ventricular Assist Device Support. <i>JACC: Heart Failure</i> , 2018, 6, 951-960.	4.1	106
30	Risk of severe primary graft dysfunction in patients bridged to heart transplantation with continuous-flow left ventricular assist devices. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1433-1442.	0.6	49
31	Combined Therapy of Ventricular Assist Device and Membrane Oxygenator for Profound Acute Cardiopulmonary Failure. <i>ASAIO Journal</i> , 2017, 63, 713-719.	1.6	4
32	Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1226-1233.	0.6	42
33	Incidence and Implications of Left Ventricular Distention During Venoarterial Extracorporeal Membrane Oxygenation Support. <i>ASAIO Journal</i> , 2017, 63, 257-265.	1.6	152
34	Angiopoietin-2: marker or mediator of angiogenesis in continuous-flow left ventricular assist device patients?. <i>Journal of Thoracic Disease</i> , 2016, 8, 3042-3045.	1.4	11
35	Reply to Spiliopoulos et al.. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 49, 1299-1299.	1.4	0
36	Durability and clinical impact of tricuspid valve procedures in patients receiving a continuous-flow left ventricular assist device. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 520-527.e1.	0.8	22

#	ARTICLE	IF	CITATIONS
37	Contemporary Outcomes of Venoarterial Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock at a Large Tertiary Care Center. <i>ASAIO Journal</i> , 2015, 61, 403-409.	1.6	71
38	Important role of mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 48, 322-328.	1.4	18
39	Feasibility of smaller arterial cannulas in venoarterial extracorporeal membrane oxygenation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, 1428-1433.	0.8	76
40	Bridge-to-Decision Therapy With a Continuous-Flow External Ventricular Assist Device in Refractory Cardiogenic Shock of Various Causes. <i>Circulation: Heart Failure</i> , 2014, 7, 799-806.	3.9	96
41	Clinical outcome of mechanical circulatory support for refractory cardiogenic shock in the current era. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 106-111.	0.6	182